Preventive Efficacy of a Tenofovir Alafenamide Fumarate Nanofluidic Implant in SHIV‐Challenged Nonhuman Primates (Adv. Therap. 3/2021)

Abstract

In article number 2000163, Alessandro Grattoni and colleagues perform the first ever HIV preventive efficacy study using a subcutaneous drug delivery implant. The implant uses a nanofluidic membrane to sustainably deliver tenofovir alafenamide fumarate (TAF), a HIV antiretroviral, without pumps or actuation. Long-term sustained TAF release, controlled through physical and electrostatic confinement in the nanochannels of the membrane, obviates daily oral dosing to provide protection from HIV infection in nonhuman primates.